Personal Genome Diagnostics and KingMed Enter Strategic Partnership to make Comprehensive Genomic Tissue Panel with TMB available in China and Hong Kong

Personal Genome Diagnostics Inc. (PGDx), a leader in cancer genomics, and KingMed Diagnostics, a laboratory services leader in China, announced today that they have entered into a strategic partnership for the PGDx elioTM tissue complete assay. KingMed Diagnostics brings substantial patient reach, encompassing 37 laboratories covering more than 21,000 hospitals and clinics. This partnership provides PGDx and KingMed Diagnostics the opportunity to serve the clinical trial screening needs of pharmaceutical partners in the Asian market through testing sites in mainland China and Hong Kong. In time and as a result of contributing data from these studies, the partners expect to also serve the clinical testing needs of patients and
physicians in those geographies upon the appropriate regulatory approvals of the PGDx elioTM assays.

The PGDx elio™ tissue complete panel is a 500+ gene test for somatic alterations that detects single nucleotide variants (SNVs), small insertion/deletions (indels), amplifications, rearrangements, microsatellite instability (MSI) and tumor mutational burden (TMB). The use of TMB and MSI for the identification of cancer patients whose tumors may be likely to respond to immune checkpoint inhibitor therapy has recently been investigated in clinical trials (TMB) and approved (MSI) by the U.S. Food and Drug Administration (FDA).

Read more here.